vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and KOSS CORP (KOSS). Click either name above to swap in a different company.

KOSS CORP is the larger business by last-quarter revenue ($2.9M vs $1.8M, roughly 1.6× INVO Fertility, Inc.). KOSS CORP runs the higher net margin — -19.8% vs -150.5%, a 130.8% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs -19.6%). KOSS CORP produced more free cash flow last quarter ($-1.1M vs $-1.8M). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs 4.2%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Koss Corporation is a company in Milwaukee, Wisconsin, US that manufactures headphones. The company created the first high-fidelity stereo headphones in 1958.

IVF vs KOSS — Head-to-Head

Bigger by revenue
KOSS
KOSS
1.6× larger
KOSS
$2.9M
$1.8M
IVF
Growing faster (revenue YoY)
IVF
IVF
+42.2% gap
IVF
22.6%
-19.6%
KOSS
Higher net margin
KOSS
KOSS
130.8% more per $
KOSS
-19.8%
-150.5%
IVF
More free cash flow
KOSS
KOSS
$712.1K more FCF
KOSS
$-1.1M
$-1.8M
IVF
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
4.2%
KOSS

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
IVF
IVF
KOSS
KOSS
Revenue
$1.8M
$2.9M
Net Profit
$-2.6M
$-565.4K
Gross Margin
29.0%
Operating Margin
-93.1%
-35.5%
Net Margin
-150.5%
-19.8%
Revenue YoY
22.6%
-19.6%
Net Profit YoY
-62.2%
-700.6%
EPS (diluted)
$-0.77
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
KOSS
KOSS
Q4 25
$2.9M
Q3 25
$1.8M
$4.1M
Q2 25
$1.9M
$3.1M
Q1 25
$1.6M
$2.8M
Q4 24
$1.7M
$3.6M
Q3 24
$1.4M
$3.2M
Q2 24
$1.8M
$2.9M
Q1 24
$1.6M
$2.6M
Net Profit
IVF
IVF
KOSS
KOSS
Q4 25
$-565.4K
Q3 25
$-2.6M
$243.7K
Q2 25
$-5.3M
$-232.7K
Q1 25
$-17.4M
$-316.7K
Q4 24
$-3.6M
$94.1K
Q3 24
$-1.6M
$-419.5K
Q2 24
$-2.2M
$-110.4K
Q1 24
$-1.6M
$-313.8K
Gross Margin
IVF
IVF
KOSS
KOSS
Q4 25
29.0%
Q3 25
40.0%
Q2 25
36.0%
Q1 25
35.2%
39.0%
Q4 24
41.4%
39.5%
Q3 24
31.0%
36.6%
Q2 24
53.1%
40.4%
Q1 24
45.3%
31.9%
Operating Margin
IVF
IVF
KOSS
KOSS
Q4 25
-35.5%
Q3 25
-93.1%
-1.1%
Q2 25
-160.4%
-14.2%
Q1 25
-1042.1%
-18.7%
Q4 24
-202.0%
-4.0%
Q3 24
-90.7%
-19.9%
Q2 24
-100.9%
-11.0%
Q1 24
-95.7%
-23.1%
Net Margin
IVF
IVF
KOSS
KOSS
Q4 25
-19.8%
Q3 25
-150.5%
6.0%
Q2 25
-283.6%
-7.5%
Q1 25
-1060.1%
-11.4%
Q4 24
-211.3%
2.6%
Q3 24
-113.8%
-13.1%
Q2 24
-122.2%
-3.8%
Q1 24
-101.3%
-11.9%
EPS (diluted)
IVF
IVF
KOSS
KOSS
Q4 25
$-0.06
Q3 25
$-0.77
$0.03
Q2 25
$-13.30
$-0.02
Q1 25
$-12.53
$-0.03
Q4 24
$14.86
$0.01
Q3 24
$-15.11
$-0.05
Q2 24
$-22.39
$-0.01
Q1 24
$-7.55
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
KOSS
KOSS
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$30.3M
Total Assets
$18.8M
$36.8M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
KOSS
KOSS
Q4 25
$15.5M
Q3 25
$16.5M
Q2 25
$15.7M
Q1 25
$13.0M
Q4 24
$9.7M
Q3 24
$11.9M
Q2 24
$14.9M
Q1 24
$9.9M
Total Debt
IVF
IVF
KOSS
KOSS
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IVF
IVF
KOSS
KOSS
Q4 25
$30.3M
Q3 25
$5.8M
$30.9M
Q2 25
$2.6M
$30.6M
Q1 25
$3.3M
$30.7M
Q4 24
$12.7M
$31.0M
Q3 24
$-23.3K
$30.8M
Q2 24
$1.4M
$31.1M
Q1 24
$10.2K
$31.1M
Total Assets
IVF
IVF
KOSS
KOSS
Q4 25
$36.8M
Q3 25
$18.8M
$37.7M
Q2 25
$19.3M
$37.2M
Q1 25
$31.7M
$37.3M
Q4 24
$46.4M
$37.4M
Q3 24
$17.0M
$38.1M
Q2 24
$17.8M
$37.2M
Q1 24
$17.3M
$37.6M
Debt / Equity
IVF
IVF
KOSS
KOSS
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
KOSS
KOSS
Operating Cash FlowLast quarter
$-1.8M
$-760.8K
Free Cash FlowOCF − Capex
$-1.8M
$-1.1M
FCF MarginFCF / Revenue
-101.6%
-37.5%
Capex IntensityCapex / Revenue
0.5%
10.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M
$-546.7K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
KOSS
KOSS
Q4 25
$-760.8K
Q3 25
$-1.8M
$762.6K
Q2 25
$-1.7M
$-534.9K
Q1 25
$-3.5M
$370.4K
Q4 24
$-617.4K
$-252.0K
Q3 24
$-640.8K
$201.6K
Q2 24
$-1.5M
$-174.0K
Q1 24
$-260.6K
$328.6K
Free Cash Flow
IVF
IVF
KOSS
KOSS
Q4 25
$-1.1M
Q3 25
$-1.8M
$761.5K
Q2 25
$-1.7M
$-541.8K
Q1 25
$-3.6M
$306.2K
Q4 24
$-696.3K
$-314.3K
Q3 24
$-155.6K
Q2 24
$-1.5M
$-174.8K
Q1 24
$-310.3K
$269.3K
FCF Margin
IVF
IVF
KOSS
KOSS
Q4 25
-37.5%
Q3 25
-101.6%
18.7%
Q2 25
-92.6%
-17.6%
Q1 25
-216.9%
11.0%
Q4 24
-40.6%
-8.8%
Q3 24
-4.9%
Q2 24
-82.3%
-6.0%
Q1 24
-19.7%
10.2%
Capex Intensity
IVF
IVF
KOSS
KOSS
Q4 25
10.9%
Q3 25
0.5%
0.0%
Q2 25
0.5%
0.2%
Q1 25
0.9%
2.3%
Q4 24
4.6%
1.8%
Q3 24
0.0%
11.2%
Q2 24
3.0%
0.0%
Q1 24
3.2%
2.3%
Cash Conversion
IVF
IVF
KOSS
KOSS
Q4 25
Q3 25
3.13×
Q2 25
Q1 25
Q4 24
-2.68×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons